A Comprehensive Evaluation of Hyperbaric Oxygen Therapy in Resuscitation Medicine - a Pilot Study (HOT-RESUS 1 Trial)
Launched by UNIVERSITY HOSPITAL, ANTWERP · Dec 2, 2022
Trial Information
Current as of January 13, 2025
Completed
Keywords
ClinConnect Summary
The HOT-RESUS 1 Trial is a study looking at how effective hyperbaric oxygen therapy (HBOT) may be for patients who have experienced a cardiac arrest and are recovering from brain injuries. In this pilot study, researchers aim to see if using HBOT is feasible, which means they want to find out if it’s practical and safe to use in these patients. If the study shows that it is feasible, they plan to conduct a larger trial to gather more information about its benefits.
To participate in this study, patients must be between the ages of 65 to 74 and have recently stabilized after a cardiac arrest. They should be stable enough to be transported for treatment. Healthy volunteers and survivors of cardiac arrest can also take part, provided they meet specific criteria, such as being able to visit the study site on their own. Participants will receive hyperbaric oxygen therapy, which involves breathing pure oxygen in a pressurized room, and they will be closely monitored throughout the process. This study is currently recruiting participants, and it’s an important step toward understanding how HBOT could help improve recovery after cardiac arrest.
Gender
ALL
Eligibility criteria
- • Depending on the study arm.
- ICU patients:
- • Inclusion criteria: sustained ROSC since a maximum of 24 hours, hemodynamic and respiratory stable enough for transportation to HBOT.
- • Exclusion criteria: traumatic CA, age \<18 years, pregnancy, (tension-) pneumothorax.
- Healthy volunteers:
- • Inclusion criteria: able to come to the study site themselves. Exclusion criteria: age \<18 years, (suspected or desired) pregnancy, known chronic illnesses, especially known claustrophobia, history of CA, history of pneumothorax, acute or chronic ear / nose condition.
- CA survivors after hospital discharge:
- • Inclusion criteria: history of CA from hospital discharge up to a maximum of 3 years ago, able to come to the study site themselves.
- • Exclusion criteria: age \<18 years, (suspected or desired) pregnancy, known claustrophobia, history of pneumothorax, acute or chronic ear / nose condition.
Trial Officials
Koen Monsieurs, Prof., MD
Study Director
University Hospital of Antwerp, Belgium
About University Hospital, Antwerp
University Hospital Antwerp is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital fosters a collaborative environment that integrates cutting-edge scientific inquiry with state-of-the-art medical practices. As a prominent sponsor of clinical trials, University Hospital Antwerp is committed to enhancing medical knowledge and improving treatment outcomes across a wide range of specialties, leveraging its expertise to contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, , Belgium
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials